Therapeutic antibodies that block the programmed death-1 (PD-1)–programmed death-ligand
1 (PD-L1) pathway can induce robust and durable responses in patients with various …

Background The combination of pembrolizumab and axitinib showed antitumor activity in a
phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. …

… Thomas Powles et al. report the results of a clinical phase I study in metastatic urothelial
bladder cancer treated with the anti-PDL1 antibody MPDL3280A. The transmembrane protein …

Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …

Background First-line chemotherapy for patients with cisplatin-ineligible locally advanced or
metastatic urothelial carcinoma is associated with short response duration, poor survival, …

Background Patients with advanced urothelial carcinoma have poor overall survival after
platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA (ctDNA) …

Background Survival outcomes are poor for patients with metastatic urothelial carcinoma
who receive standard, first-line, platinum-based chemotherapy. We assessed the overall …

Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab…

Background Patients with renal-cell carcinoma who undergo nephrectomy have no options
for adjuvant therapy to reduce the risk of recurrence that have high levels of supporting …